Navigation Links
Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

KING OF PRUSSIA, Pa., Jan. 6 /PRNewswire/ -- Prism Pharmaceuticals, Inc. announced today that Dr. Warren D. Cooper, President and Chief Executive Officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 7:30 a.m. (Pacific Time) or 10:30 a.m. (Eastern Time). The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

Dr. Cooper will present corporate strategy and highlight the recent FDA approval of the Company's new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV.

The presentation will be webcast live by visiting the Company's website at http://www.prismpharma.com. An archive of the presentation also will be available on the Company's website following the conference.

About Prism Pharmaceuticals

Prism Pharmaceuticals, based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. The product portfolio strategy is focused on recognizing unfulfilled opportunities in existing compounds that address current unmet medical needs with a specific focus on medication safety in the hospital environment.

For further information, visit http://www.prismpharma.com.


'/>"/>
SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
2. Prism glasses expand the view for patients with hemianopia
3. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
4. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
5. AUDIO from Medialink and Solvay Pharmaceuticals: New Initiative Urges Women to Address Mens Health this New Year
6. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
7. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
8. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
9. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
10. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
11. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: